Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience has entered into a $125 million revolving credit facility credit agreement, it said in a regulatory filing today.

The credit agreement, which took effect on May 24, replaces the Cincinnati-based company's loan and security agreement dated Aug. 1, 2007, and makes available to Meridian a revolving credit facility up to $125 million in aggregate amount. The credit facility expires in May 2024.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.